Open AccessPrognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
Author(s) -
Noriko Fujita,
Yukie Enomoto,
Keiko Inakami,
Tetsu Yanagisawa,
Chikage Iguchi,
Toyokazu Aono,
Takashi Nomura,
Hitoshi Yamamoto,
Tsutomu Kasugai,
Eiichi Shiba
Publication year - 2019
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000502910
Subject(s) - trastuzumab , medicine , pertuzumab , breast cancer , oncology , hazard ratio , proportional hazards model , chemotherapy , cancer , gastroenterology , confidence interval
It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast cancer patients and those after NAC among patients who did not achieve pathological complete response (pCR) using conventional adjuvant trastuzumab.